I-5508 Imatinib, Methanesulfonate Salt, >99%

Synonyms : [STI-571] [CGP-57148B] [Imatinib Mesylate]

Related Terms : [Gleevec] [Glivec] [Genfatinib]

  • Size
  • US $
  • £
  • ¥
  • 1 g
  • 48
  • 43
  • 36
  • 5,200
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 86
  • 77
  • 65
  • 9,300
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 155
  • 140
  • 117
  • 16,800
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 190
  • 171
  • 144
  • 20,600
  • Add to Cart Qty:
  • In stock
  • 25 g
  • 425
  • 384
  • 323
  • 46,100
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 589.71
  • C29H31N7O•CH4SO3
  • [220127-57-1]
  • M.I. 14: 4902

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. "Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib." Pharmacol. Rev. 55: 401-423 (2003).
  • Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. "Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase." Nat. Med. 7: 228-234 (2001).
  • Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. "Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome." Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003).
  • Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. "Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors." Mol. Cancer Ther. 5: 1007-1013 (2006).
  • The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. "AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia." Clin. Cancer Res. 11: 4941-4947 (2005).
  • Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under "Related Terms". This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies.  NOTE: THE IMATINIB, METHANESULFONATE SOLD BY LC LABORATORIES FOR RESEARCH IS NOT GLEEVEC® OR GLIVEC®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
144